Superworth

Veracyte price to free cash flow VCYT

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Nov 2, 2026
23.7×
3-year median
44.2×
Against its 3-year history
15th
percentile: 0 is its lowest day, 100 its highest
3-year range
18.8× to 292×
Peer median
25.6×

Veracyte's price to free cash flow is 23.7× as of Nov 2, 2026.

That is below its 3-year median of 44.2×, lower than on 85% of days in the last 3 years.

Over that time it ranged from 18.8× in Mar 2026 to 292× in Jul 2023.

The median for 10 diagnostics and research stocks of a similar size is 25.6×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far23.7×18.8×34.1×
202534.2×23.5×62.4×
202455.1×42.3×68.9×
202369.1×55.8×292×

Against its peers

Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first, today.

CompanyPrice to free cash flow
VCYTVeracyte23.7×
CDNACareDxn/m
BLLNBillionToOne157×
LNTHLantheus16.9×
CAICaris Life Sciences73.2×
BIOBio-Rad Laboratories27.7×
RVTYRevvity30.3×
MEDPMedpace25.6×
DGXQuest Diagnostics20.0×
LHLabcorp25.0×
NRCNRC Health24.8×
Peer median25.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Veracyte

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.